Recent headlines in the UK press have again put the issue of pharmaceutical company sponsorship of cancer initiatives under the spotlight, rekindling the debate about its dangers and its merits. Whenever a non-profit advocacy, patient or professional group opens itself up to accusations that it is acting as a front for a commercial company, all groups and all companies find themselves under suspicion. But there are many reasons to resist a knee-jerk reaction on either side to pull back from any form of cooperation.
Leave a Reply